Holen Sie sich die Stockscreener-App
22.45
4.81%
1.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Faces Lawsuit Deadline for Investor Losses - National Today
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The AI Journal
Rosen Law Firm Urges Ultragenyx Shareholders to File Claims - National Today
Mereo BioPharma Faces Deadline for Shareholder Vote - National Today
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ - MarketScreener
Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) - Bitget
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceutical Inc (RARE) - GuruFocus
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Re - GuruFocus
Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus
Ultragenyx CFO Horn Howard sells $98k in shares By Investing.com - Investing.com India
Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock - MarketBeat
Ultragenyx says gene therapy accepted for FDA review again - MSN
Ultragenyx (RARE) CFO sells 4,683 shares, retains 80,351 stake - Stock Titan
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Ultragenyx stock rating on FDA filing progress - Investing.com
Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. – RARE - ACCESS Newswire
Leerink reiterates Ultragenyx stock rating on gene therapy progress - Investing.com
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA - The Chronicle-Journal
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx (RARE) Moves Forward with FDA Review of Gene Therapy Application - gurufocus.com
Ultragenyx BLA for UX111 Accepted for FDA Review - TipRanks
If regulatory approval is obtained, production of the gene therapy UX111 by Ultragenyx Pharmaceutical Inc (RARE) will take place in the United States, with plans to proceed simultaneously at both Andelyn Biosciences and Ultragenyx's own facilities. - Bitget
FDA accepts Ultragenyx gene therapy application for rare disease - Investing.com
Ultragenyx (RARE) gets FDA review date for UX111 gene therapy on Sept. 19, 2026 - Stock Titan
FDA accepts Ultragenyx gene therapy application for rare disease By Investing.com - Investing.com UK
FDA starts review of Ultragenyx gene therapy for fatal child disease - Stock Titan
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT - MSN
Howard Horn sells multiple RARE shares (NASDAQ: RARE) under Form 144 - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE): A bull case theory - MSN
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx LawsuitRARE - PR Newswire
Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study - Insider Monkey
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action ... - Caledonian Record
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading Up 8.7%Still a Buy? - marketbeat.com
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securitie - GuruFocus
Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - Yahoo Finance
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE) - The Malone Telegram
RARE Deadline: RARE Investors with Losses in Excess of $100K Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Patient-Funded UX016 IND Clearance Might Change The Case For Investing In Ultragenyx Pharmaceutical (RARE) - Yahoo Finance
Ultragenyx Stock Gaps Down 5% Amid Weak Start and Market Concerns - Markets Mojo
Ultragenyx (RARE) Gains FDA Clearance for New Drug UX016 - gurufocus.com
Investors in Ultragenyx Pharmaceutical Inc. Should Contact - globenewswire.com
POM IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages PomDoctor Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action - GlobeNewswire Inc.
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical ... - Caledonian Record
RARE FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - GlobeNewswire Inc.
NASDAQ: RARE CLASS ACTION NOTICE - MarketScreener
Ultragenyx gains FDA IND clearance of UX016 for GNE myopathy - MSN
Ultragenyx Investors Urged to Join Securities Fraud Lawsuit - National Today
Ultragenyx Wins FDA IND Clearance for UX016 Therapy - TipRanks
Ultragenyx Announces FDA Clearance of IND for UX016 to Treat GNE Myopathy - Minichart
FDA Clears Ultragenyx IND Application for UX016 to Treat GNE Myopathy - geneonline.com
Ultragenyx Pharmaceutical Inc. Announces FDA Clearance Of Investigational New Drug Application For Ux016, A Sialic Acid Prodrug For The Treatment Of GNE Myopathy - MarketScreener
Ultragenyx (RARE) wins FDA IND clearance, plans UX016 Phase 1/2 GNE myopathy trial - Stock Titan
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy - The Manila Times
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):